STAT

FEBRUARY 29, 2024

Now, a new biotech hopes to do the same for patients with neurological conditions.  The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year. 

132

132

Drug Store News

APRIL 5, 2023

The infusion clinic is referral-based and will provide treatments for rheumatology, gastroenterology, pulmonary, neurology, dermatology, oncology and other chronic conditions.

98

98

Outsourcing Pharma

JUNE 5, 2023

Encouraging clinical data has been released by Biovie, a company developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.

88

88

Pharmaceutical Technology

JULY 26, 2022

Major symptoms of the disease are neurological and developmental disorders, as well as hepatosplenomegaly, jaundice, cholestasis, bleeding disorders and, eventually, dysphagia and even respiratory failure in adults.

Compounding 122

Compounding Labelling 122

Board Vitals - Pharmacist

AUGUST 26, 2022

The American Board of Psychiatry and Neurology (ABPN) Certification Exam in Child Neurology is a board examination that tests a candidate’s knowledge of the fundamentals of child neurology. The exam is held once a year, and is required to become board certified in Child Neurology. The exam consists of 400 questions.

Communication 98

Communication 98

European Pharmaceutical Review

MARCH 14, 2024

Boehringer Ingelheim highlighted that GPR52 is a potential emerging therapeutic target for multiple neurological and neuropsychiatric disorders. HTL0048149 began first-in-human clinical trials in 2023, according to an announcement by Sosei in July 2023. Sosei Heptares will receive an upfront payment of €25 million.

82

82

Board Vitals - Pharmacist

MAY 13, 2023

Preparing for the neurology board exam requires a comprehensive and strategic study approach. To ensure success, it is vital to utilize high-quality resources that cover the breadth and depth of neurology topics. These platforms offer a vast collection of multiple-choice questions that cover various neurology topics.

52

52

STAT

SEPTEMBER 29, 2023

In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies raised over $300 million off an audacious promise: It was going to license and develop gene therapies for at least 18 different rare and serious neurological diseases. Continue to STAT+ to read the full story…

FDA 133

FDA 133

Hospital Pharmacy Europe

APRIL 15, 2024

After a year, those given lixisenatide showed no progression of motor problems while those on placebo dropped around three points on the assessment scale – classed as a moderate difference but likely to be clinically meaningful. The UK researchers said the study was important given it supports what had previously been found with exenatide.

Hospitals 59

Hospitals 59

Pharmaceutical Technology

DECEMBER 21, 2023

Sudo plans to advance two TYK2 candidates into clinical testing next year for the treatment of autoimmune and neurologic conditions.

52

52

Outsourcing Pharma

JANUARY 13, 2023

A license agreement from UCB to Pheno Therapeutics will enable the acceleration of a promising new drug tackling neurological diseases towards clinical development.

76

76

STAT

NOVEMBER 15, 2023

In an analysis of its clinical trial , published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. Three died in 2020; the fourth died a year later.

Pharmaceutical Companies 114

Pharmaceutical Companies Pharmaceutical Companies 114

Pharma Mirror

JANUARY 10, 2021

Several studies have recently shown that the development of neurological conditions and symptoms are prevalent in COVID patients. Neurologic manifestations, including headaches, myalgias, dizziness, and encephalopathy, occur in most hospitalized COVID-19 patients.

Hospitals 98

Hospitals 98

STAT

MARCH 11, 2023

The Food and Drug Administration on Friday approved the first treatment for Rett syndrome, a genetic disease mostly affecting girls that causes severe neurologic impairments, robbing them of the ability to communicate or control muscle movement. The new drug, called Daybue, is made by Acadia Pharmaceuticals.

Communication 98

Communication FDA 98

STAT

MAY 3, 2023

Studies in human brain tissue, neural stem cells, and mice have suggested that this common virus, best known for causing cold sores, might trigger the deadly and devastating neurological disease. Read the rest…

100

100

pharmaphorum

MARCH 22, 2021

We take a look at efforts from charities, the government and digital innovators to boost awareness of rare conditions among GPs and make the clinical pathway smoother for patients. This figure comes from a new report by the Neurological Alliance , which is calling for better treatment and care for these 150,000 people.

105

105

European Pharmaceutical Review

JUNE 23, 2023

Study data from a major trial has demonstrated RNA CAR-T (rCAR-T) therapy Descartes-08 facilitated significant and long-lasting clinical improvement in generalised myasthenia gravis (gMG). This is the first clinical trial using rCAR-T to treat autoimmunity. Data from the study was published in The Lancet Neurology.

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

APRIL 12, 2024

billion, the agreement seeks to advance in vivo therapies for targets that cause serious neurological and neuromuscular diseases. The increasing presence of CRISPR-based therapies in clinical trials is anticipated to fuel further advancements in precision medicine,” Chan stated. In a deal potentially worth over $1.57

FDA 88

FDA 88

Pharmaceutical Technology

APRIL 17, 2023

At the meeting , Indiana University’s School of Medicine neurology professor Dr. Liana Apostolova said that Rexulti demonstrated statistical significance and resulted in a clinically meaningful therapeutic effect. As a member of the committee, Apostolova voted in favour of Rexulti, adding that she was convinced by the clinical data.

FDA 96

FDA Medical Schools Labelling Communication 96

Pharmafile

SEPTEMBER 12, 2023

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound NBI-1117570 in healthy adult patients.

Compounding 59

Compounding 59

STAT

JULY 13, 2023

For people living with multiple sclerosis, slowing or stopping this chronic and debilitating neurological disease often means sitting through hours-long infusion sessions, during which treatments slowly drip into a patient’s bloodstream.

96

96

STAT

MAY 17, 2023

In PKU, patients’ bodies are unable to break down the amino acid phenylalanine, resulting in intellectual disability, memory problems, and other neurological issues. He’d previously said that a 40% to 50% reduction in phenylalanine, or “Phe,” levels would be clinically important.

90

90

Pharmaceutical Technology

MAY 12, 2023

The partnership will combine Angelini Pharma’s expertise in neurological diseases with the scientific and technological strengths of JCR Pharmaceuticals for delivering biotherapeutics across the blood-brain barrier. Angelini Pharma CEO Jacopo Andreose stated: “Epilepsy is one of the most prevalent chronic neurological diseases.

52

52

European Pharmaceutical Review

MARCH 8, 2023

A placebo-controlled, Phase IIa, proof-of-concept, social anxiety clinical trial is expected to begin in the first half of 2023. An open-label, Phase IIa, proof-of-concept clinical trial in women with PPD is expected to initiate in the second half of 2023. The results are anticipated by the end of 2023.

Labelling 94

Labelling 94

STAT

FEBRUARY 17, 2023

It will once again test his willingness to apply the FDA’s doctrine of “regulatory flexibility” to a medicine with less-than-convincing clinical data.

FDA 97

FDA 97

Hospital Pharmacy Europe

JANUARY 31, 2024

It was particularly effective in detecting longitudinal changes, even in preclinical stages of the disease, the researchers reported in the journal JAMA Neurology. Research done in three separate groups of patients over eight years found the precision of the blood test was comparable to cerebrospinal fluid biomarkers.

Hospitals 52

Hospitals 52

pharmaphorum

MAY 18, 2022

Considerable scientific progress across neurological diseases and disorders was reported at the recent 74th American Academy of Neurology (AAN) Annual Meeting. One research-driven company with a strong patient focus in neurology is UCB. “In The future of epilepsy and neurology. “As

Pharmaceutical Companies 92

Pharmaceutical Companies Pharmaceutical Companies Immunization 92

European Pharmaceutical Review

DECEMBER 8, 2023

Cerevel’s pipeline includes multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson’s disease, and mood disorders. Gonzalez, chairman and chief executive officer of AbbVie.

FDA 99

FDA 99

European Pharmaceutical Review

APRIL 27, 2023

Through pre-clinical and clinical trial success, adeno-associated viral vectors (AAVs) have consistently demonstrated their effectiveness as a tool for gene delivery to treat a variety of human diseases. Since Glybera’s approval, two more AAVs have come on the market targeting neurological and ophthalmological diseases.

92

92

pharmaphorum

NOVEMBER 15, 2022

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-ranging push across cancer, immune-mediated, and neurological diseases.

Immunization 105

Immunization Compounding 105

Pharmaceutical Technology

MARCH 23, 2023

BHV-8000’s mechanistic proof of concept was showed in several pre-clinical models. We look forward to advancing BHV-8000 into clinical development and uncovering the potential of neuroimmunomodulation for severe neurological disorders in desperate need of novel treatment options.”

Immunization 105

Immunization 105

pharmaphorum

DECEMBER 15, 2021

Biogen has made a $15 million investment in digital health company TheraPanacea, which will go towards a project to find digital health tools aimed at neurological diseases. TheraPanacea meanwhile said the cash injection will be invested in expanding its existing operations and workforce in Europe.

Patient Care 68

Patient Care 68

pharmaphorum

JUNE 24, 2022

There was also a statistically significant improvement in neurological scores in people who had this type of symptom at enrolment at four weeks compared to standard care, although the two groups were equivalent on this measure at the 48-week timepoint. Symptom data mixed.

100

100

Hospital Pharmacy Europe

MARCH 6, 2023

Omaveloxolone clinical efficacy An initial dosing ranging study identified that 160 mg/day of the drug appeared to improve neurological function. Friedreich’s ataxia is an inherited autosomal recessive disease, that affects the nervous system, producing a progressive ataxia, weakness and sensory deficits.

FDA 97

FDA Specialty Pharmacies Labelling Hospitals 97

European Pharmaceutical Review

NOVEMBER 18, 2022

Upstaza is administered through a minimally invasive neurosurgical stereotactic procedure used to treat several neurological disorders in paediatric and adult patients. Upstaza clinical trials. The efficacy and safety profile of Upstaza has been shown across clinical trials and compassionate use programmes.

126

126

pharmaphorum

DECEMBER 17, 2020

The big Swiss pharma already has a presence in neurology with its multiple sclerosis drug Gilenya (fingolimod) and the more recently approved Aimovig (erenumab). With the acquisition of Cambridge, Massachusetts-based Cadent, Novartis gains rights to a portfolio of neurology drugs.

98

98

pharmaphorum

DECEMBER 11, 2022

He sat down with pharmaphorum at Frontiers Health 2022 in Milan to discuss how his group approaches digital innovation around neurological diseases. Some symptoms of neurological diseases are very subjective, and evaluation timepoints are spread out over long periods of time. “We AI gets us closer to personalised medicine.”.

Hospitals 137

Hospitals 137